ANIX - Anixa Biosciences Inc logo

Anixa Biosciences Inc

ANIX

Anixa Biosciences develops cancer therapies and vaccines, focusing on ovarian cancer treatments using chimeric antigen receptor-T cell technology. The company also explores vaccines for breast cancer and other malignancies, targeting unmet medical needs.

โš•๏ธ Healthcare NASDAQ Listed 1987 $ USD
$1,000 invested 30 years ago โ†’$15today

Score Overview

1 Year
Scoreโ€”
Net Growth28.47%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.9
Net Growth39.63%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-55.81%
Net Trend60%
Net Income Consistency
Rev Growth-100.00%
Rev Trend38%
Revenue Consistency
20 Years
Score2.5
Net Growth-2.83%
Net Trend55%
Net Income Consistency
Rev Growth-100.00%
Rev Trend39%
Revenue Consistency
30 Years
Score
Net Growth-44.74%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev Trend43%
Revenue Consistency
All Time
Score
Net Growth-458.29%
Net Trend46%
Net Income Consistency
Rev Growth-100.00%
Rev Trend32%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Anixa Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ANIX

1996: 70.5% ยท 2021: 42.4% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 2.79โ€”
1 Year2025-09-26
$ 3.40-17.94%
5 Years2021-09-28
$ 4.99-44.09%
10 Years2016-09-28
$ 3.15-11.43%
20 Years2006-09-28
$ 14.63-80.92%
30 Years1996-09-27
$ 181.25-98.46%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 7M$ 13M
2025$ 0.00-$ 10M$ 15M
2024$ 0.00-$ 12M$ 19M
2023$ 210K-$ 9M$ 23M
2022-$ 13M$ 29M
2021$ 512K-$ 12M$ 35M
2020$ 0.00-$ 10M$ 9M
2019$ 250K-$ 11M$ 5M
2018$ 1M-$ 13M$ 5M
2017$ 362.5K-$ 5M$ 6M
2016$ 300K-$ 5M$ 3M
2015$ 9M-$ 1M$ 6M
2014$ 3M-$ 9M$ 5M
2013$ 388.85K-$ 10M$ 898.17K
2012$ 940.01K-$ 4M$ 839.69K
2011$ 1M-$ 7M$ 3M
2010$ 730.67K-$ 5M$ 1M
2009$ 1M-$ 16M$ 2M
2008$ 2M-$ 5M$ 1M
2007$ 486.85K-$ 5M$ 1M
2006$ 508.65K-$ 7M$ 1M
2005$ 439.79K-$ 4M$ 506.52K
2004$ 494.46K-$ 3M$ 1M
2003$ 244.22K-$ 3M$ 1M
2002$ 5M-$ 3M$ 854.82K
2001$ 1M-$ 3M$ 1M
2000$ 1M-$ 4M$ 1M
1999$ 100K-$ 8M$ 2M
1998$ 100K-$ 7M$ 5M
1997$ 100K-$ 5M$ 12M
1996$ 100K-$ 5M$ 22M
1995$ 100K-$ 3M$ 8M
1994$ 100K-$ 3M$ 6M
1993$ 100K-$ 2M$ 8M
1992$ 100K-$ 1M$ 4M
1991$ 100K-$ 1M$ 4M
1990$ 100K-$ 1M$ 2M
1989$ 100K-$ 1M$ 2M
1988$ 100K-$ 1M$ 1M
IPO1987$ 100K-$ 1M$ 700K
ANIX - Anixa Biosciences Inc logo

Anixa Biosciences Inc fundamental performance

Between 2020 and 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 10M to -$ 10M. Revenue increased in 0 of those 5 years; net income in 3.

Between 2015 and 2025, revenue declined from $ 9M to $ 0.00 and net income went from -$ 1M to -$ 10M. Revenue increased in 4 of those 10 years; net income in 6.

Anixa Biosciences Inc currently holds a 20-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.

Membership

Continue ANIXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies